- Home
- VERV
as 11-15-2024 4:00pm EST
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 382.5M | IPO Year: | 2021 |
| Target Price: | $25.75 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.30 - $19.34 | Next Earning Date: | 11-05-2024 |
| Revenue: | $24,396,000 | Revenue Growth: | 219.91% |
| Revenue Growth (this year): | 84.66% | Revenue Growth (next year): | -41.58% |
Latest Verve Therapeutics Inc. News
VERV Breaking Stock News: Dive into VERV Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating
Simply Wall St.
11 days ago
Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
12 days ago
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
12 days ago
Verve Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
12 days ago
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
GlobeNewswire
16 days ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
a month ago
State Street Corp's Strategic Acquisition in Verve Therapeutics
Insider Monkey
a month ago
Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5?
Compare VERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERV Verve Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.